Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib (CP-690,550) in Dry Eye Disease
NCT00784719Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of INN-04-01 in dry eye disease (DED) (6 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Systemic Adverse Events at 8 weeks, Percentage of Participants With Ocular Adverse Events at 8 weeks and 2 more. Started Nov 2008; status: completed.
02
Drugs
INN-04-01
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT00784719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784719.